Goldwater 2010

Methods	Randomised clinical trial
Participants	32 adult treatment‐naive participants with HCV genotype1 Country: USA
Interventions	Experimental group: oral 150 mg, 300 mg, 450 mg of GS‐9256 as a single dose. Control group: placebo.
Outcomes	HCV RNA, pharmacokinetics.
Notes	The trial also had groups with healthy volunteers.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	The trial was described as being placebo blinded, but it was unclear how the blinding was performed
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	The trial was described as being placebo blinded, but it was unclear how the blinding was performed
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No data
Selective reporting (reporting bias)	Unclear risk	No protocol could be obtained
Vested‐interest bias	High risk	The trial was funded by Gilead Sciences
Other bias	Low risk	The trial appeared to be free of other components that could put it at risk of bias